Philippe Autier, MD, PhD
This article was published at www.annals.org on 12 January 2016.
Disclosures: The author has disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-2789.
Requests for Single Reprints: Philippe Autier, MD, PhD, University of Strathclyde Institute of Global Public Health, Espace Européen, Building G, Allée Claude Debussy, 69130 Ecully, France; e-mail, email@example.com.
Autier P.; Efficient Treatments Reduce the Cost-Efficiency of Breast Cancer Screening. Ann Intern Med. 2016;164:297-298. doi: 10.7326/M15-2789
Download citation file:
Published: Ann Intern Med. 2016;164(4):297-298.
Published at www.annals.org on 12 January 2016
The primary objective of cancer screening and treatment is to reduce the risk for cancer death. Screening may reduce this risk by detecting cancer at an early stage in its development when it is asymptomatic and curable. A combination of therapeutic methods specific to disease stage at diagnosis and other cancer and patient characteristics influence the risk for cancer death. Efficient treatment methods are usually available for cancer diagnosed when it is still local, but this availability wanes when cancer is diagnosed at a more advanced stage. Thus, by “down-staging,” or identifying cancer at an early stage, screening decreases the burden of advanced-stage cancer, for which treatments are less efficient or nonexistent. In this issue, Birnbaum and colleagues (1) estimate whether the availability of efficient adjuvant and chemotherapy treatments would have modified reductions in the risk for breast cancer death reported in randomized trials of breast cancer screening.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Hematology/Oncology, Breast Cancer, Cancer Screening/Prevention, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only